Diallo Lab

Jean-Simon Diallo profile picture

Contact Information

Jean-Simon Diallo
613-737-8899 x 75203
jsdiallo@ohri.ca

Ottawa Hospital Research Institute
Centre for Cancer Therapeutics
501 Smyth Road
Box 926
Ottawa, ON
K1H 8L6

News

Vaccines and viral immunotherapies: unique Canadian program provides training to manufacture biotherapeutics
November 21, 2020 - As COVID-19 highlights the urgent need to increase vaccine manufacturing around the world, a unique training program is bolstering Canada’s capacity to manufacture vaccines, as well as viral immunotherapies for cancer and other emerging ...
The Ottawa Hospital and uOttawa launch new cancer immunotherapy research projects with funding from BioCanRx
September 22, 2020 - BioCanRx, Canada’s Immunotherapy Network, today announced funding of $10M for 14 cancer immunotherapy research projects and eight core and biomanufacturing facilities across the country. Researchers at The Ottawa Hospital (TOH) and the University ...
Virus and targeted drug synergize to fight cancer in mice
August 26, 2020 - While some cancer cells can be killed quickly by a single drug, the reality for patients is that multiple therapies are often required, especially if resistance develops. A new study led by Dr. Jean-Simon Diallo reveals for the first time that ...
COVID-19 research on cell therapy, drug screening and marginalized populations funded through Ontario’s Rapid Research Fund
May 21, 2020 - Researchers from The Ottawa Hospital, affiliated with the University of Ottawa, have been awarded almost $2 million from Ontario’s COVID-19 Rapid Research Fund for three research projects that could help in the fight against the virus. These ...
COVID-19 research moving at ‘lightning speed’, thanks to generous community support
May 8, 2020 - Researchers at The Ottawa Hospital are working around the clock to advance more than 50 potentially life-saving research projects to support the world-wide effort to find better ways to treat and prevent COVID-19. Now, nine of these projects have ...
Researchers join the fight against COVID-19
April 2, 2020 - As hospitals and communities band together to fight COVID-19, researchers at The Ottawa Hospital are harnessing their unique expertise and resources to help.
MS drug makes cancer-fighting viruses more effective in lab models
February 7, 2018 - A drug used to treat multiple sclerosis and psoriasis can dramatically enhance the spread of cancer-fighting viruses in human tumour samples and animal models, according to a study published in Science Translational Medicine. A team led by Dr. Jean
The Ottawa Hospital awarded $12.7M for research, double the national CIHR success rate
January 30, 2018 - Sixteen research groups at The Ottawa Hospital, affiliated with the University of Ottawa, have been awarded $12.7 million in the most recent project grant competition from the Canadian Institutes of Health Research (CIHR). This represents a success r
Could viruses take cancer immunotherapy to the next level? Study shows viruses and checkpoint inhibitors work together to cure resistant breast cancer in mice
January 3, 2018 - Immunotherapy, which helps the body’s immune system attack cancer, has revolutionized treatment for cancers such as melanoma and leukemia. However, many other kinds of cancer remain resistant. A new study led by researchers at The Ottawa Hospital and
“Bait and switch” approach stimulates immune attack on cancer
December 20, 2017 - Oncolytic (cancer-fighting) viruses have shown promise in the lab and the clinic because they can directly kill cancer cells while also stimulating the immune system to attack the cancer. Dr. Jean-Simon Diallo and his team recently discovered a novel
Cancer-fighting viruses: Canadian team to accelerate research with $7.4 million from Terry Fox Research Institute
September 27, 2017 - Imagine a tiny army of viruses entering a tumour, making thousands of copies of themselves and busting up cancer cells as they spread. Now imagine the body’s immune system coming in to fight off the virus and eliminate the remaining cancer cells at
Viral therapy effective against rare bone and muscle cancers in lab models
July 18, 2017 - Cancers that arise in the bone, muscle and connective tissues (called sarcomas) are relatively rare and difficult to treat. Dr. Jean-Simon Diallo and Dr. Hesham Abdelbary teamed up to see if viruses that have proven effective in other cancer ...
Ottawa researchers to play lead role in new cancer immunotherapy studies
February 15, 2017 - BioCanRx funds research into CAR-T and virus-infected cell therapy Researchers from The Ottawa Hospital and the University of Ottawa will play a lead role in cutting-edge research on cancer immunotherapy, thanks to five new peer-reviewed researc
Virus-chemo combination therapy shows promise in breast cancer models
August 24, 2016 - Researchers in Dr. John Bell’s group and Dr. Jean-Simon Diallo’s group have discovered that a cancer-fighting virus called Maraba-MG1, together with a common chemotherapy called paclitaxel, can slow the growth of breast cancer in animal models an
Researchers find a way to supercharge cancer-fighting viruses
June 14, 2016 - A research team led by Drs. Jean-Simon Diallo, Christopher Boddy and Jeffrey Smith has created a new molecule that could help cancer-fighting viruses be more effective against a wider variety of tumours. Engineered viruses that destroy cancer ...
Virus vs. Prostate Cancer: Canadian Researchers Pioneer Next-generation Therapy -- Prostate Cancer Canada and the Movember Foundation partner to make innovative work possible
September 30, 2015 - A multi-disciplinary team of scientists and clinicians led by Dr. John Bell of The Ottawa Hospital is developing a treatment for prostate cancer using viruses that destroy cancer cells and boost the anti-cancer immune response, all the while leaving
Viruses and drugs combine to form potent anti-cancer therapy
April 22, 2015 - Dr. Jean-Simon Diallo and his colleagues have discovered that compounds that disrupt our cells’ inner skeleton (called microtubule-destabilizing agents) can greatly enhance oncolytic virus cancer therapy in mouse and cell culture models. As described